Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Exclusion Criteria

• •Uncertain clinical diagnosis of peanut allergy
• •History of severe or life threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening
• •Severe persistent asthma or uncontrolled mild or moderate asthma
• •History of eosinophilic esophagitis, other eosinophilic gastrointestinal disease, severe gastroesophageal reflux disease, symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology
• •History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema
• •History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension
• •History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen